Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
Heidelberg Pharma AG today announced that it has secured a financing commitment in the amount of up to EUR 36 million from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). This commitment replaces the not yet fully used financing commitment from March 2021.
The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma as well as dievini at a later date.
The financing commitment will enable Heidelberg Pharma to advance its business activities, in particular to completely conduct the clinical Phase I/IIa with HDP-101 and to further develop the candidates HDP-102 und HDP-103, if and to the extent that this is not achieved through potential alternative capital measures. Based on the current planning, the Company’s cash reach is secured until mid-2023.